Overview

Our ADP-A2AFP SPEAR T-cell product targets alpha- fetoprotein (AFP) is being investigated in an ongoing Phase I clinical trial for the treatment of patients with hepatocellular carcinoma (liver cancer).

Pipeline

SPEAR
T-cell
Target Indications Target dose (Cohort) 5 BN+
(expansion)
Registration
studies
100 M (1) 1 BN (2) 5 BN (3)
ADP-A2AFP AFP Hepatocellular carcinoma
100 M (1) Phase complete
1 BN (2) Phase in progress
5 BN (3) Phase not started
5 BN+ (expansion) Phase not started
Registration studies Phase not started